Ablynx

HematologyInflammatory diseasesOncologyRespiratory and Pulmonary

Ablynx

Biopharmaceutical company Ablynx is engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, hematology, oncology and pulmonary disease.

Biopharmaceutical company Ablynx (Euronext Brussels: ABLX) is engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, hematology, oncology and pulmonary disease.

The company has approximately 25 programs in the pipeline and six Nanobodies at clinical development stage. Nanobodies have been generated against more than 235 different disease targets and has characterized potent antagonists in vitro against 38 different targets. The company and its collaborators have obtained positive in vivo efficacy data from animal studies in eight major therapeutic programs in five disease areas.

Ablynx’'s in-house lead programs in the clinic, ozoralizumab, caplacizumab, and ALX-0061 are in Phase II clinical development. Ozoralizumab, an anti-TNF-alpha Nanobody achieved positive clinical proof-of-concept in a Phase II study in patients with active rheumatoid arthritis in May 2011. Ablynx is currently looking for a partner to license this product.

Caplacizumab is a Nanobody targeting von Willebrand factor (vWF) and is being evaluated in patients with thrombotic thrombocytopenic purpura (TTP). ALX-0061 is Nanobody that binds IL-6 receptor. It reported excellent safety and efficacy Phase IIa results at week 24 in February 2013.

Ablynx’s anti-RANKL program to treat bone-related disorders, ALX-0141, has completed a Phase I study. Ablynx is currently looking for a partner to license this product.

Ablynx’s first inhaled Nanobody, ALX-0171, has the potential to be a first-in-class therapeutic to treat respiratory syncytial viral infections (RSV). Positive safety results were published in September 2012 and additional safety and pre-clinical studies will be performed throughout 2013. The first-in-infant study is expected to start in 2014.

Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The company is headquartered in Ghent, Belgium.


Latest Articles

Who's Who

Parexel

Parexel

Back to top